Latest updates for Gild
Fresh curated links around GILD are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Gilead projects $107M Q1 earnings headwind due to recent R&D deals
- Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
- Gilead Sciences Is Doubling Down On Acquisitions
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't
Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
<![CDATA[Gilead Enters $5 Billion Agreement to Acquire Tubulis ]]>
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis
Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple cancer medicines already in clinical testing.
Meet the Glorious Gold ETF Crushing the S&P 500, the Nasdaq-100, and the Dow Jones in 2026
The shiny yellow metal is on track for another great year as investors hedge against economic uncertainty.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.